Titan Pharmaceuticals Revenue and Competitors

Claim your profile

Location

$44.7M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Titan Pharmaceuticals's estimated annual revenue is currently $5.4M per year.(i)
  • Titan Pharmaceuticals's estimated revenue per employee is $139,487
  • Titan Pharmaceuticals's total funding is $44.7M.

Employee Data

  • Titan Pharmaceuticals has 39 Employees.(i)
  • Titan Pharmaceuticals grew their employee count by -2% last year.
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$4.7M619%$53MN/A
#2
$34.3M17717%$110MN/A
#3
$0.4M2735%$236.7MN/A
#4
$34.5M178-5%$160MN/A
#5
$3.7M2420%N/AN/A
#6
$147.3M3212%$192.5MN/A
#7
$17.5M113-3%$24.1MN/A
#8
$2.7M4379%N/AN/A
#9
$34.1M220100%N/AN/A
#10
$47.1M304-3%N/AN/A

Titan Pharmaceuticals Inc. is developing proprietary therapeutics primarily for the treatment of serious medical disorders. The company's lead product is Probuphine®, the first and only commercialized treatment of opioid dependence to provide continuous, around-the-clock blood levels of buprenorphine for six months following a single procedure. It was approved by the U.S. Food and Drug Administration in May 2016 and is being commercialized in the U.S. by partner Braeburn Pharmaceuticals. Probuphine employs Titan's proprietary drug delivery system ProNeura, which is capable of delivering sustained, consistent levels of medication for up to 12 months. The ProNeura technology has the potential to be used in developing products for treating other chronic conditions such as Parkinson's disease and hypothyroidism, where maintaining consistent, around-the-clock blood levels of medication may benefit the patient and improve medical outcomes.

keywords:N/A

$44.7M

Total Funding

39

Number of Employees

$5.4M

Revenue (est)

-2%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Titan Pharmaceuticals News

2022-04-19 - Activist Investing Announces 5.6% Ownership Interest in Titan Pharmaceuticals, Inc. - Benzinga

... today filed a Schedule 13D announcing its acquisition of approximately 5.6% of the common stock outstanding of Titan Pharmaceuticals,...

2022-04-17 - Opioids Agonist Drugs Market Size, Scope And Forecast ...

Purdue Pharma, Titan pharmaceuticals, Boehringer Ingelheim, Janssen Pharmaceuticals, Inc, Sanofi, Sun Pharmaceuticals,...

2022-04-13 - Titan Pharmaceuticals (NASDAQ:TTNP) Coverage Initiated at ...

The firm set a “hold” rating on the specialty pharmaceutical company's stock. TTNP opened at $0.82 on Tuesday. Titan Pharmaceuticals has a 52...

2019-09-04 - Why Investors remained confident on- Titan Pharmaceuticals ...

On Tuesday, Titan Pharmaceuticals, Inc. (NASDAQ:TTNP) reached at $0.49 price level during last trade its distance from 20 days simple ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$5.3M3944%N/A
#2
$5.3M405%N/A
#3
$4.5M4043%N/A
#4
$4.4M40-9%N/A
#5
$35M4121%N/A